JPWO2019213245A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019213245A5
JPWO2019213245A5 JP2020561795A JP2020561795A JPWO2019213245A5 JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5
Authority
JP
Japan
Prior art keywords
months
accumulated
composition
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523126A5 (https=
JP2021523126A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030184 external-priority patent/WO2019213245A1/en
Publication of JP2021523126A publication Critical patent/JP2021523126A/ja
Publication of JP2021523126A5 publication Critical patent/JP2021523126A5/ja
Publication of JPWO2019213245A5 publication Critical patent/JPWO2019213245A5/ja
Pending legal-status Critical Current

Links

JP2020561795A 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法 Pending JP2021523126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666459P 2018-05-03 2018-05-03
US62/666,459 2018-05-03
PCT/US2019/030184 WO2019213245A1 (en) 2018-05-03 2019-05-01 Methods for reducing accumulated pathologic tau protein

Publications (3)

Publication Number Publication Date
JP2021523126A JP2021523126A (ja) 2021-09-02
JP2021523126A5 JP2021523126A5 (https=) 2022-05-10
JPWO2019213245A5 true JPWO2019213245A5 (https=) 2022-05-10

Family

ID=66530499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561795A Pending JP2021523126A (ja) 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法

Country Status (4)

Country Link
US (1) US20210137861A1 (https=)
EP (1) EP3787750A1 (https=)
JP (1) JP2021523126A (https=)
WO (1) WO2019213245A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076332B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Treatment of lysosomal storage disorders
EP3784795A4 (en) 2018-04-27 2022-01-19 The Regents Of The University Of California INHIBITION OF LIPOFUSCIN AGGREGATION BY MOLECULAR TWEEZERS
CN115151250A (zh) * 2020-02-24 2022-10-04 欧博拉托股份有限公司 用于治疗癌症或肿瘤的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0737208T3 (da) * 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
AU2003291358A1 (en) * 2002-11-07 2004-06-03 Molecular Geriatrics Corporation Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
CN110248650A (zh) * 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法

Similar Documents

Publication Publication Date Title
JP2019537582A5 (https=)
JP2021523126A5 (https=)
JP2011527339A5 (https=)
JP2025060686A5 (https=)
JP2002537340A5 (https=)
RU2007102698A (ru) Композиции и способы лечения неврологических нарушений
JP2015523346A5 (https=)
US12121513B2 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JPWO2019213245A5 (https=)
JP2007535498A5 (https=)
JP2020504154A5 (https=)
JP2018505218A5 (https=)
JP2020527138A5 (https=)
CN101547695B (zh) 具有改进的加替沙星眼内渗透性的含水液体制剂
US20210137861A1 (en) Methods for reducing accumulated pathologic tau protein
CN1447688A (zh) 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法
US20230201151A1 (en) Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
CN102716123A (zh) 一种用于治疗IgA肾病复方制剂
JP2021522205A (ja) 敗血症および敗血症性ショックの治療
Dasenbrook et al. Anti-inflammatory therapies for cystic fibrosis
Parish et al. The treatment of acne vulgaris with low dosage doxycycline
JPWO2021186245A5 (https=)
EP3322482B1 (en) Topical ciprofloxacin compositions
JPWO2023173005A5 (https=)
US20240148779A1 (en) Methods for the treatment of proteinopathies